Cambrex Corporation (CBM) : Fridays money flow analysis of Cambrex Corporation (CBM) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $12.05 million. In comparison, the inflow of money on upticks was a meager $4.04 million. The dollar value of composite uptick trades minus the downtick trades was negative $8.01 million. The uptick to downtick ratio of 0.34 in the money flow shows weakness. The downtick transaction value was high at $8.61 million, which denotes distribution on strength.. Hence, the net money flow in the stock was negative ($8.61 million). Cambrex Corporation (CBM) gained $0.34 at $43.17, a change of 0.79% over the previous days close.
The company Insiders own 2.63% of Cambrex Corporation shares according to the proxy statements. Institutional Investors own 99.96% of Cambrex Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -28.01%.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Cambrex Corp, Korb William B had sold 3,420 shares worth of $188,100 in a transaction dated July 11, 2016. In this transaction, 3,420 shares were sold at $55 per share.
Cambrex Corporation (NYSE:CBM): The stock opened at $43.47 and touched an intraday high of $43.47 on Friday. During the day, the stock corrected to an intraday low of $42.83, however, the bulls stepped in and pushed the price higher to close in the green at $43.27 with a gain of 0.23% for the day. The total traded volume for the day was 303,685. The stock had closed at $43.17 in the previous trading session.
Cambrex Corporation (CBM) : During the past 4 weeks, traders have been relatively bearish on Cambrex Corporation (CBM), hence the stock is down -10.11% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.2% relative to the S&P 500. The 4-week change in the price of the stock is -10.23% and the stock has fallen -1.7% in the past 1 week.
Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Companys customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Companys products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and, to a lesser extent, other fine chemicals. Cambrex has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment.